Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

88% daily adherence for prescription gummies, new securities law investigation, 14% implied move on 10 Aug results

Sources (5)

HIMS's first prescription gummy (Biotin plus Minoxidil, for hair growth) has posted an 88% daily adherence rate, which goes straight to the core weak point of the telehealth subscription model. Adherence is a leading variable for retention and efficacy, and it is two sides of the same coin as the subscription engine at the centre of the FTC's allegations.

Read more

Meanwhile the law firm Kessler Topaz launched a securities law investigation on 5 Aug, confirming that the FTC lawsuit is spilling over into securities class action risk. At $30-31, the shares have already priced in most of the peptide upside and the rebound. The Q2 results after the close on 10 Aug, with the margin ramp as the key test, are the binary event that will settle matters, and options imply a 14% single-day move.

Key evidence

  • The Biotin plus Minoxidil hair-growth gummy, launched in June 2025, is HIMS's first prescription gummy product
  • A survey of 300 users a year after launch found that 88% said they take it every day
  • 82% said they find it easier to stick with the gummy format than with what they used before
  • Nearly two thirds would not go back to pills after trying it
  • On 5 Aug the law firm Kessler Topaz Meltzer & Check opened an investigation into potential securities law violations at HIMS
  • Before that came the FTC lawsuit of 29 Jul and at least two data privacy class actions recorded on 2 May
Show 5 more
  • Closed at $30.82 on 3 Aug (+10.98%) and $30.92 after hours, already about 5.1% above its level before the FTC lawsuit
  • Options data (Bloomberg/Investing.com): the 10 Aug results imply a single-day move of about 14%
  • Q2 results are confirmed for after the close on 10 Aug (4 days away)
  • On MarketBeat's basis the price target is $31.43. Reuters and FactSet both show a Hold rating, with 4 Buys and 11 Holds, so analysts are sitting on the fence.
  • On a 13-analyst basis the price target has fallen to $30.15 (implying +3%), and BofA maintains Neutral at $37

Catalysts to watch

  • 10 Aug after the close: Q2 results, the binary event that will settle this round, with the margin ramp as the key test
  • 2026 guidance is heavily weighted to the second half, so the question is whether management lays out a credible path for margins to ramp
  • Further disclosure on the peptide product line
  • Progress on securities class actions: whether the Kessler Topaz investigation escalates into a formal lawsuit
  • Progress of the FTC lawsuit

Risks

  • The FTC's allegations about the subscription engine, at least two data privacy class actions and a new securities law investigation: legal pressure keeps stacking up
  • If the margin ramp falls short of expectations in the 10 Aug results, the implied 14% single-day move means large downside exposure
  • The current price already reflects most of the peptide upside, so part of the positive expectation has been used up
  • Sell-side consensus price targets of $30-31 sit on the fence, with no consensus on an upside catalyst
  • The core weak point of the telehealth subscription model remains: the gummy adherence data comes from a sample of only 300 people

Sources 5

  1. Business Insider and other reports (company disclosure of gummy adherence data)
  2. Kessler Topaz Meltzer & Check law firm announcement (5 Aug)
  3. Bloomberg / Investing.com options data
  4. MarketBeat / Reuters / FactSet sell-side consensus
  5. BofA research note

A brief is a lead for our research, not a verified conclusion or advice.